WuXi Biologics announced its interim results, with net profit attributable to shareholders of approximately RMB 2.339 billion, a year-on-year increase of 56%

WuXi Biologics announced its mid-year results for 2025, with revenue of approximately 9.953 billion yuan, a year-on-year increase of 16.1%; gross profit of approximately 4.253 billion yuan, a year-on-year increase of 27%; and net profit attributable to the company's owners of approximately 2.339 billion yuan, a year-on-year increase of 56%. Basic earnings per share are 0.58 yuan. The revenue growth is mainly attributed to the successful execution of the "Follow and Win Molecules" strategy, the advantages of its technology platform, and project delivery capabilities. During the reporting period, 86 new comprehensive projects were added, bringing the total to 864, with the total amount of uncompleted orders increasing to 20.3 billion USD